Levetiracetam versus Phenobarbital for Neonatal Seizures: A Retrospective Cohort Study.

Publication

Levetiracetam versus Phenobarbital for Neonatal Seizures: A Retrospective Cohort Study.

Journal Paper/Review - Oct 22, 2022

Bättig Linda, Dünner Corinne, Cserpan Dorottya, Rüegger Andrea, Hagmann Cornelia, Schmitt Bernhard, Pisani Francesco, Ramantani Georgia

Citation

Bättig L, Dünner C, Cserpan D, Rüegger A, Hagmann C, Schmitt B, Pisani F, Ramantani G. Levetiracetam versus Phenobarbital for Neonatal Seizures: A Retrospective Cohort Study. Pediatr Neurol 2022; 138:62-70.

Type

Journal Paper/Review (English)

Journal

Pediatr Neurol 2022; 138

Publication Date

Oct 22, 2022

Issn Electronic

1873-5150

Pages

62-70

Brief description/objective

Although phenobarbital (PB) is commonly used as a first-line antiseizure medication (ASM) for neonatal seizures, in 2015 we chose to replace it with levetiracetam (LEV), a third-generation ASM. Here, we compared the safety and efficacy of LEV and PB as first-line ASM, considering the years before and after modifying our treatment protocol.